Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Mbarara, Uganda, 1410
- Mbarara Regional Referral Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Term mothers [38-41 WOA] above 18 years of age admitted at Mbarara Hospital, Uganda in active labor; anticipating vaginal delivery -
Exclusion Criteria:
Complicated labor:
- confirmed intra-uterine fetal death
- self-reported maternal heart disease
- current diagnosis of severe malaria or acute bacterial infection,
- multiple pregnancy,
- induced or augmented labor,
- elective Caesarean section,
- ante-partum hemorrhage,
- reported hypersensitivity to prostaglandins
- altered cognitive status (ACS) as assessed by the MRAs. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A: sublingual misoprostol 600µg
Misoprostol is a uteretonic drug
|
Is a prostaglandin
Other Names:
|
|
Placebo Comparator: Arm B: 10 IU Oxytocin
Oytocin is a standard of care treatment for PPH
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimated Blood loss
Time Frame: 24 hours
|
Estimated blood loss of more than or equal to 500ml
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood loss of more than 1000ml
Time Frame: 24 hours
|
Other secondary outcomes are: Hematocrit drop, additional uteretonic use
|
24 hours
|
|
1) maternal death, 2) pre and post delivery hemoglobin changes 3) pre and post delivery hematocrit changes 4) >10% hemoglobin drop 5) mean postpartum hemoglobin and hematocrit, 6) mean measured blood loss
Time Frame: 24 hours
|
24 hours
|
|
|
7) placental retention 8) requirement for blood transfusion 9) requirement for additional therapeutic procedures or uterotonics 10) duration of the third stage of labor
Time Frame: 24 hours
|
24 hours
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uteretonic use
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Amon Agaba, PhD, Mbarara University of Science and Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pregnancy Complications
- Obstetric Labor Complications
- Puerperal Disorders
- Death
- Uterine Hemorrhage
- Parental Death
- Hemorrhage
- Postpartum Hemorrhage
- Maternal Death
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Reproductive Control Agents
- Anti-Ulcer Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Oxytocics
- Misoprostol
Other Study ID Numbers
Other Study ID Numbers
- MUST-17-2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.